Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus

 Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus

Moleculin Collaborates with UTMB to Evaluate WP1122 for Multiple Viruses Including Coronavirus

Shots:

  • Moleculin will provide its lead candidate, WP1122, and related inhibitors along with technical support while UTMB will investigate candidates against multiple viruses including COVID-19, in connection with UTMB’s CBEID
  • UTMB’s CBEID collaborates with the Galveston National Laboratory, which is funded by NIAID the US Department of Defense, the US Centers for Disease Control & Prevention and other federal agencies along with academic partners, private foundations, and the biopharmaceutical industry
  • WP1122 is a prodrug of 2-DG (2-deoxy-D-glucose) that overcome 2-DG’s lack of drug-like properties and demonstrated increment in the tissue/organ concentration in its preclinical study

Click here ­to­ read full press release/ article | Ref: Moleculin | Image: Moleculin

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post